Boston Scientific (NYSE:BSX) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Co. (NYSE:BSX). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on March 17th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 4/1/2025.
• Sold $1,001 – $15,000 in shares of W. R. Berkley (NYSE:WRB) on 4/1/2025.
• Sold $15,001 – $50,000 in shares of GoDaddy (NYSE:GDDY) on 4/1/2025.
• Purchased $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 3/31/2025.
• Purchased $1,001 – $15,000 in shares of Boeing (NYSE:BA) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Hologic (NASDAQ:HOLX) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/31/2025.

Boston Scientific Trading Up 3.3 %

BSX traded up $2.98 during trading on Wednesday, reaching $93.62. The company had a trading volume of 11,008,072 shares, compared to its average volume of 6,267,382. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 52 week low of $66.80 and a 52 week high of $107.17. The stock has a market cap of $138.47 billion, a P/E ratio of 74.82, a PEG ratio of 2.79 and a beta of 0.73. The business has a 50 day simple moving average of $101.18 and a 200-day simple moving average of $93.78.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently made changes to their positions in the stock. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $25,000. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 260 shares during the period. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 210 shares in the last quarter. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Finally, Global Wealth Strategies & Associates grew its stake in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BSX. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Citigroup boosted their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Barclays increased their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Wells Fargo & Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.91.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 133,183 shares of company stock valued at $13,948,476. Insiders own 0.50% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.